Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $64.00 at Stifel Nicolaus

Intellia Therapeutics (NASDAQ:NTLA) had its target price lowered by Stifel Nicolaus from $80.00 to $64.00 in a report published on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts also recently issued reports on NTLA. Truist Financial reiterated a buy rating and issued a $120.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. Evercore ISI upgraded Intellia Therapeutics to a strong-buy rating in a research note on Friday, August 9th. JPMorgan Chase & Co. lowered their target price on Intellia Therapeutics from $61.00 to $55.00 and set an overweight rating for the company in a research note on Monday, August 12th. Canaccord Genuity Group restated a buy rating and set a $73.00 target price on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Finally, Cantor Fitzgerald restated an overweight rating and set a $65.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $61.77.

Intellia Therapeutics Trading Up 0.6 %

Shares of NASDAQ NTLA opened at $20.24 on Wednesday. Intellia Therapeutics has a 12-month low of $19.21 and a 12-month high of $38.71. The company has a market cap of $2.06 billion, a P/E ratio of -3.78 and a beta of 1.77. The stock has a fifty day moving average price of $23.47 and a 200 day moving average price of $24.57.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period in the prior year, the company posted ($1.40) EPS. The company’s quarterly revenue was down 48.5% compared to the same quarter last year. On average, sell-side analysts forecast that Intellia Therapeutics will post -5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Blue Trust Inc. grew its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. First Horizon Advisors Inc. boosted its position in Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the period. GAMMA Investing LLC grew its stake in Intellia Therapeutics by 1,322.0% during the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after buying an additional 2,459 shares during the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in shares of Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.